The EID2B Knockout HAP1 Polyclonal Cells represent a polyclonal population of HAP1 cells engineered via CRISPR/Cas9-mediated gene disruption to create a loss-of-function model for the EID2B gene. This polyclonal knockout model provides a heterogeneous pool of edited cells, each carrying distinct disruption events, enabling robust functional studies of EID2B in a near-haploid genetic background. The product is designed for advanced biomedical research applications, offering a reliable system to dissect EID2B-dependent transcriptional regulation and cellular processes.
The HAP1 host cell line is a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia (CML) line, exhibiting fibroblast-like morphology and a male karyotype. Its near-haploid genome simplifies genetic manipulation and knockout generation, as only one allele needs to be targeted, making it a widely adopted system for high-throughput functional genomics, CRISPR screens, and targeted gene disruption studies. The CML origin provides a cancerous background, which is relevant for studying oncogenic signaling and tumor suppressor mechanisms.
EID2B functions as a transcriptional repressor by directly interacting with the histone acetyltransferase EP300/p300 and impairing its acetyltransferase activity, thereby suppressing p300-dependent transcriptional activation. This repression mechanism is linked to the regulation of cell differentiation and cell cycle progression. EID2B is activated downstream of cell cycle-dependent transcription factors, including members of the E2F family, and interacts with CREBBP/CBP and HDAC complexes to modulate chromatin structure. It represses transcription of key downstream targets such as CDKN1A and other p53 target genes, while also influencing MYC expression, thereby promoting maintenance of an undifferentiated, proliferative state.
In the HAP1 background, disruption of EID2B provides a powerful system to dissect its role in transcriptional repression and cell fate decisions. The near-haploid genome ensures that the knockout effect is not masked by a second functional allele, while the CML origin enables exploration of EID2B??s function in a leukemia-relevant context. The polyclonal nature of the cell population minimizes the risk of clonal-specific artifacts and allows the assessment of EID2B-dependent phenotypes across a spectrum of editing events. Loss of EID2B is expected to relieve repression of p300 target genes, potentially accelerating differentiation or inducing cell cycle arrest, thus offering insights into its role in cancer and developmental disorders.
These polyclonal knockout cells are suitable for a broad range of functional genomics applications, including the validation of EID2B target genes by RNA-seq or RT-qPCR, and protein interaction studies via co-immunoprecipitation followed by western blotting. Flow cytometry and proliferation assays can be employed to examine the impact of EID2B loss on cell cycle progression and growth, while differentiation assays and reporter gene assays enable detailed investigation of transcriptional repression and p300/CBP signaling. The cells serve as a versatile tool for studying the EID2B regulatory network in cancer biology and differentiation research. For additional information, please contact Ascent Research.
